Document:

Exhibit 4.4

  

BioPharma
Ltd.

 

Private & Confidential

 

September 21, 2005

 

Avigdor Kaplan

18 Hashirion St.

Raanana

 

Dear Avigdor,

 

		1	This letter records the terms on which you are invited to serve as a Non-Executive Chairman of
the Board of Directors of Can-Fite Biopharma Ltd (the “Company”) and confirms the agreement previously reached
between us. This arrangement shall be effective as of June 20, 2005, the date on which you were appointed as a director of the
Board of Directors of the Company.

 

		2	Your appointment is to continue unless you terminate this
arrangement upon giving the Company not less than two (2) months’ written notice which may be given at any time, provided that
such notice does not expire before the end of the said period. However, your appointment will terminate forthwith, without any
entitlement on your part to compensation, if:

 

		(i)	you are not reappointed as a director at any Company annual
general meeting where you are required to retire under the Articles of Association of the Company (as amended from time to time);

 

		(ii)	you cease to be a director by reason of your vacating
office pursuant to any provision of the Articles of Association of the Company (as amended from time to time) or the Israeli Companies
Act – 1999 (the “Act”);

 

		(iii)	you are convicted of any criminal offence (excluding minor road traffic offences);

 

		(iv)	you breach the terms of this appointment (such breach not being capable of remedy); or

 

		(v)	you are guilty of gross misconduct or any act in any way which may, in the opinion of the Board, bring the Company into disrepute
or discredit.

 

    	1

    	 

    

 

BioPharma
Ltd.

 

		3	In addition, commencing from the listing of the Company’s ordinary shares for trading on the Tel-Aviv Stock Exchange, you shall
be entitled to receive a monthly management fee equal to NIS 15,000 (plus VAT), to be paid to you on a monthly basis, within ten
(10) days from the end of each calendar month, such payment to made as a salary payment from the Company, which shall deduct from
such amount any and all applicable deductions required by law.

 

		4	Furthermore, you shall be granted options to purchase 2,000,000 ordinary shares of the
                                                         Company representing 2% of the issued and outstanding share capital of the Company on a pre-money valuation basis as of the
                                                         date hereof (the “Options”). The exercise price of the Options shall be equal to NIS 1.125 per each option. The
                                                         Options shall be subject to the same terms and conditions as all current employee options which are 48 months, monthly
                                                         vesting so that 1/48 of the Options shall vest at the end of each calendar month following the grant of options. The Options
                                                         shall be granted to you following the approval of the shareholders at a duly convened shareholders meeting which we expect
                                                         shall take place no later than September 30, 2005.

 

		5	In the event of termination of this appointment (otherwise than on termination in accordance
                                                         with paragraphs 2 (ii) to (v) inclusive of this letter) you will be entitled to that proportion of the salary due and
                                                         unpaid,                                                          accrued on a daily basis up to and including the date
                                                         of termination of the appointment.

 

		6	In the event that you are called on or requested to perform any special duties or responsibilities outside your ordinary duties
as Director the Board may agree to pay you special remuneration.

 

		7	As a Non-Executive Chairman you will perform the duties normally attendant on that office,
                                                         including (without limitation) attending meetings of the Board of Directors (you may attend either in person or through
                                                         telephone attendance). Non-Executive Directors are expected to work with and through the Board; they are not expected to
                                                         undertake executive duties or to assume executive responsibilities.

 

		8	During
the term of your appointment you may not (except with the prior sanction of a resolution of the Board) be directly or indirectly
employed, engaged, concerned or interested in, or hold any office in, any business or undertaking which competes with any of the
businesses of the Company. However, this shall not prohibit you from holding (directly or through nominees or trustees) investments
listed with any recognised stock exchange which compete with the business of the Company so long as you do not hold more than
3 per cent of the issued shares or other securities of any class of any one company without the prior sanction of a resolution
of the Board.

 

		9	Both during the term of your appointment and after its
termination you will observe the obligations of confidentiality which are attendant on the office of director. In addition, although
they are not specifically mentioned in this letter, you will of course be subject to the normal legal duties and responsibilities
of a director of a company incorporated under the Act.

 

    	2

    	 

    

 

 

BioPharma Ltd.

 

		10	Upon termination of this appointment you will resign from
your office as a director of the Company and from all other appointments or offices which you hold as nominee or representative
of the Company.

 

		11	This letter shall be governed by Israeli Law.

 

Kindly confirm your agreement to the terms set out above
by signing the endorsement on the enclosed copy of this letter and returning the copy to me at the above address.

 

	Yours sincerely,
	 
	for and on behalf of CAN-FITE BIOPHARMA LTD.
	 
	 	/s/ Pnina Fishman	 
	Prof. Pnina Fishman, CEO and Director

 

I agree to the above terms of my appointment.

 

Dated: September 21, 2005

 

	 	/s/ Avigdor Kaplan
	 	Avigdor Kaplan

 

    	3Exhibit 4.5

 

CONSULTING
AGREEMENT

 

CONSULTING
AGREEMENT (the “Agreement”), dated as of September 27, 2005, by and between CAN-FITE BIOPHARMA LTD., an Israeli Company,
whose address is 10 Bareket Street, Petach Tikva, Israel (the “Company”), and BioStrategics Consulting Ltd through
its President, Dr. Michael H. Silverman, whose place of business is 9 Elizabeth Road, Marblehead, MA, USA (the “CONSULTANT”).

 

WHEREAS,
the Company is currently engaged in the research and development of therapeutics that function through binding to or interacting
with adenosine receptors (the “Field”);

 

WHEREAS,
the CONSULTANT has the necessary know-how, qualifications and experience in the Field required in order to provide the consulting
services as herein set forth;

 

WHEREAS,
the Company desires to appoint the CONSULTANT as a Medical Director, and the CONSULTANT desires to be appointed by the Company,
as a consultant to the Company in a role of Medical Director and in connection thereof, to provide to the Company with medical
and clinical research and development consulting services in the Field (the “Services”), as hereinafter set
forth.

 

NOW
THEREFORE, in consideration of the mutual undertakings and premises herein contained, the parties hereto hereby agree as follows:

 

		1.	The Appointment

 

		1.1	Subject to the terms hereof, the Company hereby appoints the CONSULTANT, and the CONSULTANT hereby
agrees to be appointed by the Company as a CONSULTANT to the Company in connection with the Services to be provided by the CONSULTANT
pursuant to Section 2 hereof. In rendering the Services hereunder, the CONSULTANT shall be deemed to be, and he is, an independent
contractor, and neither this Agreement nor the performance of any of the terms hereof will or will be deemed to constitute or create
any other relationship between the Company and the CONSULTANT.

 

		1.2	Without
                                                           derogating from any other provision herein, the CONSULTANT
                                                           acknowledges and agrees that during the term hereof (a) the
                                                           Company is free at all times to appoint other consultants, or to use
                                                           its own employees, in connection with any
                                                           of the services to be provided by the CONSULTANT
                                                           pursuant to Section 2 hereof, and (b) the CONSULTANT
                                                           will exercise reasonable care and diligence
                                                           to prevent, and will not take, any action or condition which
                                                           could result in a conflict with, or prejudicial to, the interests of
                                                           the Company.

 

    	1

    	 

    

 

		2.	Representations of the CONSULTANT

 

The
CONSULANT hereby represents to the Company that:

 

		2.1	He has the know-how, experience, qualifications and capacity to provide the Services to the Company
in the Field as set forth in this Agreement.

 

		2.2	The execution, delivery and the terms of this Agreement (i) will not constitute a default or breach
of any agreement or other instrument to which the CONSULTANT in party or by which he is bound, and (ii) does not require the consent
of any person or entity.

 

		2.3	In performing his Services hereunder, the CONSULTANT shall not utilize any proprietary information
of any third party.

 

		2.4	He is not employed, providing consulting services, has rights of representation, marketing agency
or any other right whatsoever of any other company or entity which competes, directly or indirectly, with the Company and the business
currently carried on by the Company.

 

		2.5	He will not, now or in the future, have any claim or claims whatsoever to any right of any kind
except as set forth in this Agreement.

 

		2.6	To the best of his knowledge, this Agreement and the provision of the Services by the CONSULANT
are not in conflict and do not breach any law, rule or regulation that govern the CONSULTANT.

 

		3.	Extent and Scope of Services

 

		3.1	During the term hereof, the CONSULTANT shall provide the services to the Company, to the affairs
and business of the Company and during such period will provide the Company with such consulting services as may be reasonably
requested of it, from time to time, by the CEO of the Company or any other person or firm designated by the CEO. The consulting
concerns clinical and medical research and development activities within the Field.

 

		3.2	The CONSULTANT shall render the Services, as required by the Company, on such dates, at such time
as shall be required by the Company, from his home office, and/or any other location agreed upon between the parties.

 

		3.3	During the term hereof, the CONSULTANT shall keep the Company currently informed as to his activities
hereunder and shall, periodically, provide the Company with written reports setting forth the Services provided by him.

 

    	2

    	 

    

 

		3.4	The parties hereby agree that the CONSULTANT is not deemed to be an agent or a representative of
the Company and therefore does not possess any authority, whether actual or apparent, to represent the Company or to contractually
commit the Company in any way or manner.

 

		4.	Compensation

 

In
consideration of the services provided to the Company by the CONSULTANT hereunder, the Company shall compensate the CONSULTANT
as follows:

 

		4.1	The Company agrees to pay the CONSULTANT a Consulting fee of three hundred twenty-five US dollars
($325) per hour. The aforementioned notwithstanding, the maximal pay for any single day’s work, will not exceed US$ 2,600.

 

		4.3	It is agreed by the parties hereto that reasonable pre-approved expenses in written incurred by
the CONSULTANT in the discharge of his duties under this Agreement, including travel expenses will be borne by the Company, and
reimbursed forthwith on request.

 

		4.4	In calculating the time incurred by the CONSULTANT, traveling time shall not be included in the
calculation. In the reimbursement of expenses as set forth in Section 4.3 above, it is agreed that the Company will reimburse CONSULTANT
for air travel in a coach class or equivalent, unless agreed otherwise before a specific travel.

 

		4.5	Payment and reimbursement shall be made to such bank account, as the CONSULTANT will indicate,
within twenty-one (21) business days from the date of obtaining such invoices by the Company.

 

		4.6	The payment provided by this Agreement shall be made to the CONSULTANT after deduction of all taxes
and deductions at source required by law to be deducted. The parties hereto agree, that all taxes, social insurance payments, pension
payments, health insurance and any other such payments, shall be borne solely by the CONSULTANT. The Company shall not pay nor
be liable to pay any taxes upon the payment to the CONSULTANT of any remuneration as set forth in this Agreement. CONSULTANT hereby
undertakes to indemnify and reimburse the Company for any amounts claimed or levied on the Company due to taxes, social insurance
payments, pension payments, health insurance and any other such payments resulting from any payment made by the Company to the
CONSULTANT under this Agreement

 

		4.7	The Company shall not undertake any social insurance premiums, pension payment and health insurance
on the name of the CONSULTANT.

 

    	3

    	 

    

 

		4.8	The CONSULTANT shall undertake, at his own expense, sufficient insurance coverage against illness,
injuries and/or damages incurred by him in connection of his render of services in accordance with this Agreement.

 

		5.	Confidential Information

 

		5.1	In the course of providing services
                                                           to the Company hereunder, The CONSULTANT may have access to, and become
                                                           familiar with, “Confidential Information” of the Company
                                                           (as hereinafter defined). The CONSULTANT shall at all times hereinafter
                                                           maintain in the strictest confidence all such Confidential Information
                                                           and shall not divulge any Confidential Information to any person, firm
                                                           or corporation with the prior written consent of the Company. For purposes
                                                           hereof, “Confidential Information” shall mean all
                                                           information in any and all medium which is confidential by its nature,
                                                           including, without limitation, data, technology, know-how, inventions,
                                                           discoveries, designs, processes, formulations, models, and/or trade
                                                           and business secrets relating to any line of business in which the
                                                           Company is involved. Confidential Information will also include the
                                                           Company’s marketing and business plans relating to current, planned,
                                                           old or future products.

 

		5.2	The CONSULTANT shall not use Confidential
                                                           Information for, or in connection with, the development, manufacture
                                                           or the use of any product or for any other purpose whatsoever except
                                                           as and to the extent provided in
                                                           this Agreement or in any other subsequent agreement between the parties.

 

		5.3	Notwithstanding the foregoing, Confidential Information shall not include information which the
CONSULTANT can evidence to the Company by appropriate documentation; (i) is in, or enters the public domain otherwise than by reason
of a breach hereof by the CONSULTANT; (ii) is known by The CONSULTANT at the time of disclosure thereof by the Company; (iii) is
independently developed by the CONSULTANT without recourse to Confidential Information; or (iv) is rightfully transmitted or disclosed
to the CONSULTANT by a third party which owes an obligation of confidentiality with respect to such information.

 

		5.4	All Confidential Information made available to, or received by, the CONSULTANT shall remain the
property of the company, and no license or other rights in or to the Confidential Information is granted hereby, the obligation
of the CONSULTANT is not to use any Confidential Information disclosed pursuant to this Agreement except as provided in this Agreement,
shall remain in effect indefinitely, and the CONSULTANT shall be prohibited from disclosing any such Confidential Information during
the term of this Agreement thereafter.

 

    	4

    	 

    

 

		5.5	All files, records, documents, drawings, specifications, equipment and similar items relating to
the business of the Company, whether prepared by the CONSULTANT or otherwise coming into his possession, and whether classified
as Confidential Information or not, shall remain the exclusive property of the Company. Upon termination or expiration of this
Agreement, or upon request by the Company, the CONSULTANT shall promptly turn over to the Company all such files, records, reports
analysis, documents and other material of any kind concerning the Company which the CONSULTANT obtained, received or prepared pursuant
to this Agreement.

 

		6.	Proprietary
                                                                                                   Information

 

		6.1	Definition of “Proprietary Information”. Contractor understands that the Company possesses
and will possess Proprietary Information which is important to its business or proposed business. In addition, Company frequently
conducts business and receives information from other parties with which it has a business relationship (collectively, “Business
Affiliates”) that is confidential in nature. For purposes of this Agreement, “Proprietary Information” is all information,
whether conveyed orally or in writing or in any other intangible or tangible form, that was or will be developed, created, or discovered
by or on behalf of the Company, or which became or will become known by, or was or is conveyed to the Company (including, without
limitation, “Results” as defined above), which has or may have commercial value to the Company or to the Company or to
Business Affiliates. “Proprietary Information” may include, but is not limited to, patents, copyrights, trade secrets,
techniques, data, databases, sketches, drawings, models, inventions (whether patentable or not), works of authorship, know-how,
processes, apparatus, equipment, formulae and confidential information related to the current future and proposed products and
services of the Company, and also includes, without limitation, Company’s respective information concerning research, clinical
studies, experimental work, development, design details and specifications, formulations, competitive analyses, chemical compounds
and variations thereof, excipients and other ingredients, masking and flavoring strategies, clinical and product development plans,
engineering, financial information, pricing, procurement requirements, purchasing, manufacturing, customer lists, business forecasts,
sales and merchandising and marketing plants and information, the duties, salaries and terms of compensation of employees or Business
Affiliates of the Company. “Proprietary Information” also includes proprietary or confidential information of any other
third party who may disclose such information to Company or Contractor in the course of Company’s business.

 

    	5

    	 

    

 

		6.2	Ownership of Proprietary information; Assignment. All ownership rights in Proprietary Information
and any other intellectual or industrial property of any sort anywhere in the world (collectively “Rights”) shall be
the sole and exclusive property of the Company. Contractor hereby assigns to the Company (and shall ensure any employees or agents
of Contractor shall assign) any Rights Contractor may have or acquire in such Proprietary Information by performing the Services
hereunder. At all times, both during the term of this Agreement and after its termination, Contractor will keep in confidence and
trust and will not use or disclose any Proprietary Information or anything related to it without the prior written consent of an
officer of the Company. Contractor shall take appropriate measures to ensure that its employees and agents, if any, arc bound to
the requirements set forth in such a manner that such party and/or its successor(s) will be able to honor its/their confidentiality
and nonuse obligations under this Agreement. Contractor acknowledges that any disclosure or unauthorized use of proprietary Information
will constitute a material breach of this Agreement and cause substantial harm to the Company for which monetary damages would
not be a fully adequate remedy and therefore, in the event of any such breach, in addition to any other available remedies, the
Company shall have the right to seek injunctive relief without the need to secure a bond

 

		7.	Non-Competition

 

		7.1	The CONSULTANT shall not at any time during the term
of this Agreement, directly or indirectly, engage in (as owner, stockholder,partner, director, officer, employee, consultant
or otherwise, except as an investor in a corporation whose stock is publicly traded and in which he holds less than 3% of the
outstanding shares) any business, which competes in any way with the Company’s business.

 

		7.2	The CONSULTANT shall not at any time during the term of this Agreement and for two (2) years thereafter,
solicit any employee, customer, or supplier of the Company to cease or change its legal or business relationship with the Company.

 

		8.	Terms and Termination

 

		8.1	Subject to provisions of Section 7.3 of this Agreement shall take effect from the date set out
above as of which this Agreement is deemed to be entered into and shall continue in full force and effect for a period of one (1)
year from such dale, Unless terminated as provided herein, the Agreement will be automatically renewed for consecutive one year
periods.

 

		8.2	Notwithstanding Section 7.1 above, either party may given notice to the other party terminating
this Agreement by providing the other party with thirty (30) days prior written notice. However, in accordance with the provisions
of Section 7.3 hereof, either party may given notice to the other party terminating this Agreement immediately upon the occurrence
of the events specified in Section 7.3 below.

 

		8.3	(a)     The Company shall have the right to terminate this Agreement “for
cause”, at any time, by giving the CONSULTANT notice of termination “for cause”, slating the reasons constituting
the “cause”. In such event, this Agreement shall be terminated as to the lime of delivery of the said notice. For purposes
hereof “cause” shall mean (a) a breach of trust by the CONSULTANT, including without limitation, acts of moral turpitude,
theft, embezzlement or self-dealing; (b) the disclosure of Confidential Information of or in relation to the Company to any third
party; or (c) material breach by the CONSULTANT of this Agreement, such breach not remedied within (30) thirty days after service
of notice by the Company on the CONSULTANT specifying the breach complained or and (if remediable) requiring remedy of it.

  

    	6

    	 

    

 

(b)     The
CONSULTANT shall have the right to terminate this Agreement “for cause”, at any lime, by giving to the Company notice
of termination “for cause”, stating specifically the reasons constituting the “cause”, in such event, this
Agreement shall be terminated as of the time of delivery of the said Notice. For the purposes hereof “cause” shall mean
(a) a material breach by the Company of this Agreement which breach shall not have been remedied within (30) thirty days of service
of a notice in writing by the CONSULTANT on the Company requiring remedy of such breach; or (b) the Company becoming bankrupt or
insolvent or ceasing or threatening to cease to carry on business or being unable to pay its debts as they fall due or a receiver
or other encumbrances being appointed to the undertaking and assets, or any material part thereof of the Company; or (c) a change
in the controlling shareholders of the Company, such that persons not currently controlling the Company become controlling shareholders
of the Company. For the purpose of this section, the term “control” means controlling the management of the Company
by either (1) holding or owning more than 50% of the voting shares of the Company, or (2) having the right to designate more than
50% of the directors of the Company.

 

		9.	Miscellaneous

 

		9.1	Any notice under this Agreement shall be in writing, to the addresses of the Company or the CONSULTANT
as set out above, and shall be deemed to have been duly given for all purposes (ft) seven (7) days after delivery of documents
to a courier such as FedEx for dispatch to either party; or (b) upon manual delivery, to the respective addresses or faxes set
forth above or to such other address of which notice as aforesaid has actually been received.

 

		9.2	This Agreement is the entire agreement between the parlies with respect to the subject matter hereof,
and supersedes all prior understandings, agreements and discussions between them, either written or oral, with respect to such
subject matter.

 

		9.3	This Agreement shall not be modified or amended except by a written instrument signed by the parties
hereto. No waiver or failure to act with respect to any breach or default hereunder, subsequent breach or default, whether of similar
or of different nature.

 

		9.4	This Agreement shall be governed by, interpreted and construed in accordance with the laws of the
State of Israel. The competent court in Tel Aviv, Israel shall have sole and exclusive jurisdiction regarding any dispute or claim
arising hereunder.

 

    	7

    	 

    

 

		9.5	Unless provided to the contrary in this Agreement, the CONSULTANT shall not assign this Agreement
to any third party, in whole or in part. The Company may assign this Agreement to any of its affiliate, upon the provision of written
notice to the CONSULTANT.

 

		9.6	Any provision hereof which is found to be invalid, illegal or unenforceable under any applicable
provision of valid laws, shall be amended to the extent required to render it valid, legal and enforceable under such laws (or
deleted if no such amendment is feasible), and such amendment or deletion shall not effect the enforceability of the other provisions
hereof.

 

		9.7	The Parties agree that failure of either party at any time to require performance by the other
Party of any of the provisions herein shall not operate as a waiver of the right of that party to request siriet performance of
the same or like provisions, or any other provisions hereof, at a later time.

 

IN
WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.

 

	CAN-FITE BioPharma Ltd.	 	The CONSULTANT
	 	 	 	 	 
	By: 	/s/ Pnina Fishman	 	By:	/s/ Michael H. Silverman
	Dr. Pnina Fishman	 	Dr. Michael H. Silverman

 

    	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]